An interventional study of electroencephalography, electrocardiogram, pupillometry, evoked potentials, light administration and transcutaneous vagus nerve stimulation, electroencephalography, pupillometry, electrocardiogram, light administration in Refractory Epilepsy, sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain. Recruiting at 1 site in Belgium. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Drug Resistant Epilepsy with a site in Belgium — 5 open to participants now, 6 under way, 1 of them phase 3. Drug Resistant Epilepsy · Belgium.
Among the 17 studies in Drug Resistant Epilepsy with a site in Belgium, this one is the 9th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2023, is one of 8 with no phase, and was the 11th registered.
258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.
Browse Drug Resistant Epilepsy studies →5 of the 17 studies in Drug Resistant Epilepsy with a site in Belgium are open now. Recruiting first, the newest first:
Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Sites in Belgium
Ages 3+
Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Sites in Belgium
Ages 18–79
University Hospital, Ghent · Sites in Belgium
Ages 18+
Biohaven Therapeutics Ltd. · Sites in Belgium, United States, Argentina and 24 more countries
Ages 18–75
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 68 Drug Resistant Epilepsy studies recruiting now, 27 (40%) set no upper age limit and 40 (59%) stop at 75 or younger; 27 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 3
First in 2012; this study’s year is marked. 2 started in 2023.
This study's planned enrollment of 34 is above the median of 30 across 202 interventional studies indexed under Drug Resistant Epilepsy.
Median enrollment 40 across the 15 interventional studies, 509 across the 2 observational. Of the 10 that completed or were terminated, 3 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 17 have an industry lead sponsor. The 10 most frequent:
Cliniques universitaires Saint-Luc- Université Catholique de Louvain is the lead sponsor of 350 studies on the registry; 64 are open to participants now.
Cliniques universitaires Saint-Luc- Université Catholique de Louvain has 4 studies filed under Drug Resistant Epilepsy — fewer than ten, so there is no comparison to draw.
2 of the studies in Drug Resistant Epilepsy with a site in Belgium that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06132893Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | 2026-12 |
| NCT06443463Biohaven Therapeutics Ltd.Long-term Safety and Tolerability of BHV-7000 | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Drug Resistant Epilepsy with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Vagus nerve stimulation (VNS) is an adjunctive treatment for refractory epilepsy. Although widely used, there is still a substantial number of patients with insufficient response. Light, and particularly blue light, can stimulate alertness, attention and cognition through modulation of anatomical targets which are common to the vagal afferent network. This project aims at understanding how exposure to blue enriched light may influence VNS effects in patients with refractory epilepsy by exploring the modulation of a series of biomarkers of VNS action. This could possibly lead to new therapeutic strategies to increase efficacy of VNS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients:
VNS implanted since at least 3 months age >18-60 years; IQ >55 on Wechsler scale (normal status or mild cognitive impairment)
healthy participants aged between 18 and 35 years without any medical history (neurological / psychiatric disease)
Exclusion criteria:
Patients:
other medical implanted devices than VNS, ocular diseases
Helthy participants:
medical implanted devices, cerebral trauma, ocular disease
Patients will not receive any drugs, but will participate to experiments involving electroencephalograpy, pupillometry and light administration.
Other: electroencephalography, electrocardiogram, pupillometry, evoked potentials, light administration
Subjects will not receive any drugs, but will participate to experiments involving electroencephalograpy, pupillometry and light administration.
Other: transcutaneous vagus nerve stimulation, electroencephalography, pupillometry, electrocardiogram, light administration
Recording of the electrical activity of the brain, of the heart. Pupil size will be analyzed. The effect of blue light administration will be assessed on those parameters.
Transcutaneous vagus nerve stimulation will be performed in helathy subjects, as well as the recording of the electrical activity of the brain, and of the heart. Pupil size will be analyzed. The effect of blue light administration will be assessed on those parameters.
Effect of blue light on VNS biomarkers
Blue light increases VNS induced electroencephalogram desynchronisation in implanted patients
Time frame: 4 years
Effect of blue light on VNS biomarkers
Blue light increases P300 amplitude in VNS implanted patients
Time frame: 4 years
Effect of blue light on VNS biomarkers
Blue light increases VNS (or tVNS) induced pupil dilation (in patients \& healthy subjects).
Time frame: 4 years
Ran from Jul 2023 to primary completion in Jul 2023, 0 months.
Of 90 non-industry interventional studies with no phase under Drug Resistant Epilepsy, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21. This study's 0 months is below that.
Counting every sponsor, half of 102 studies reached it within 34 months; a quarter within 21 and three quarters within 50.
Completion moved once since we started tracking on Sep 25, 2026: Apr 2026 → Dec 2026, on Nov 2, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cliniques universitaires Saint-Luc- Université Catholique de Louvain →